Achieving a peak aminoglycoside concentration (C max )/MIC of >10 within 48 h of initiation of therapy for pneumonia caused by gram-negative organisms results in a 90% probability of therapeutic response by day 7. Targeting an MIC of 1 g/ml, empirical aminoglycoside loading doses of 348 (25th-to 75th-percentile range, 275 to 432) mg were calculated to obtain a C max /MIC of 10 in our patient population. Individualized pharmacokinetic monitoring coupled with MIC data should determine subsequent dosing regimens to minimize the potential for toxicity and maximize the probability of clinical response.
Aminoglycosides have been used for treating a wide variety of serious infections for over 30 years. However, few data exist on how best to maximize dosages and scheduling to achieve the best therapeutic outcome for a given patient. As aminoglycosides exhibit concentration-dependent killing, peak concentrations (C max ) and C max /MIC ratios have been postulated to be the best predictors of therapeutic efficacy (5, 6, (8) (9) (10) (11) (12) 14) . Traditionally, aminoglycosides have been administered in clinician-determined doses (i.e., similar doses for patients of similar weight) or with individualized pharmacokinetic monitoring (IPM) with C max targets associated with efficacy (8-10, 12, 14) . However, since aminoglycosides show concentration-dependent killing, it appears more appropriate to target the pharmacodynamic parameter C max /MIC in an attempt to optimize efficacy (7) .
In patients with documented pneumonia caused by gramnegative organisms, data demonstrate that achieving a C max / MIC ratio of Ն10 within 48 h of initiation of therapy results in a 90% probability of temperature and leukocyte count normalization by day 7 of therapy (7) . Clinician-determined and C max target dosing methods may lead to a delay in reaching appropriate C max /MIC ratios. The aim of this analysis was to determine an initial aminoglycoside dosing regimen to immediately achieve pharmacodynamic parameters predictive of optimization of therapeutic response in patients with pneumonia caused by gram-negative organisms.
(This work was presented in part at the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, Calif., 1997.)
This was a retrospective analysis of prospectively collected pharmacokinetic data for 78 consecutively treated adult medical and surgical patients admitted to Bassett Healthcare from 1983 to 1993. All data were collected by the Clinical Pharmacy Service. Patients with pneumonia caused by gram-negative organisms who received gentamicin or tobramycin for Ն72 h were eligible for analysis. Diagnosis of pneumonia was done according to the Centers for Disease Control criteria (2): (i) a new, otherwise unexplained pulmonary infiltrate on a chest radiograph, (ii) growth of a sole pathogenic organism in a purulent sputum culture, and (iii) leukocytosis (Ͼ10,000/mm 3 ) and/or fever (Ն38°C). Patients with cystic fibrosis or neutropenia were excluded.
Initial aminoglycoside dosing regimens were chosen by the patient's physician (clinician-determined method) and only altered if the regimen was found to be a significant overdose or underdose by empirical calculations with hospital-specific patient population pharmacokinetic parameters (1) . Pharmacokinetic analysis was performed within 72 h of initiation of therapy with the collection of one predose serum concentration, recording of the duration and time of dose infusion, collection of one postdistributional serum concentration at least 30 min after the end of the infusion, and collection of one postdose serum concentration at least one estimated half-life after the first postdose concentration.
Pharmacokinetic data were analyzed by the method of Sawchuk and Zaske (13) , fitting the data to a one-compartment, intravenous-infusion model. Aminoglycoside doses were modified to obtain a 1-h C max of 7 to 10 g/ml and a minimum concentration (C min ) of Ͻ2 g/ml before redosing (C max target method). By the Microscan system (Dade, West Sacramento, Calif.) the MIC at which 90% of the isolates are inhibited (MIC 90 ) of both gentamicin and tobramycin for sterile body fluid isolates (nonurine) of Escherichia coli, Serratia marcesens, and Citrobacter, Klebsiella, Enterobacter, and Proteus species at Bassett Healthcare for 1996 was Ͻ1 g/ml. The MIC 90 for P. aeruginosa was 5 g of gentamicin/ml and 1 g of tobramy-cin/ml. Using patient-specific pharmacokinetic parameters and the MIC 90 of 1 g of tobramycin/ml, we modeled an empirical aminoglycoside loading dose to achieve a C max /MIC of 10 (thus, a C max of 10 g/ml). The following equation was used to determine these doses (13) :
Ϫkelt2 , where C max is 10 mg/liter at time t 2 , k o is the aminoglycoside infusion rate in milligrams per hour, k el is the elimination rate constant in hour Ϫ1 , V is the volume of distribution in liters, t 1 is the infusion duration in hours (set at 1 h), and t 2 is the length of the distribution phase (set at 1.7 h secondary to the prolonged distribution time for larger aminoglycoside doses) (4).
Definitive aminoglycoside regimens for achieving a C max / MIC of 10 by using the MIC for the organism isolated in each patient (which in all cases was Յ8 g/ml) were also determined by the following equations (13): ϭ ln (C max /C min )/k el , where is the dosing interval in hours and C min is 0.5 g/ml; and MD ϭ Table 1 . This was an elderly population with some degree of renal impairment. Measured pharmacokinetic parameters are shown in Table 2 .
Assuming an MIC of 1 g/ml, an empiric median tobramycin loading dose of 348 (275 to 432) mg (or 5.3 [4.3 to 6.7] mg/kg of total body weight) would have achieved a postdistributional C max of at least 10 g/ml and a C max /MIC ratio of at least 10 in 50% of our patient population. A 7 mg/kg loading dose of tobramycin would achieve an initial C max of at least 10 g/ml in 90% of our patients. Utilizing patient-specific pharmacokinetic parameters and the isolated-bacterium-specific MIC, a definitive aminoglycoside dose of 460 (280 to 1,160) mg, or 7.0 (4.2 to 17.0) mg/kg, given every 8, 12, 18, 24, 36, 48, and 60 h in 14, 25, 26, 19, 10, 3, and 3% of our patients, respectively, would have achieved a C max of 10 (5 to 40) g/ml, a C max /MIC of 10, and a C min of 0.5 g/ml in all patients. Figure 1 compares the median first C max /MIC ratio that would be achieved in these patients for a range of aminoglycoside MICs for three different dosing regimens: an empirical 7-mg/kg loading dose, the traditional C max target method, and the clinician-determined dosing method. The traditional C max target method and the clinician-determined method would only achieve the C max /MIC target ratio of 10 for MICs of Յ0.5 g/ml, while a 7-mg/kg loading dose would achieve C max /MIC targets for MICs of Յ1 g/ml in 90% of the subjects and would reach a median C max /MIC of 6.6 (5.2 to 8.1) for an MIC of 2 g/ml and 3.3 (2.6 to 4.1) for an MIC of 4 g/ml. Using a large loading dose followed by IPM, and MIC data once available, should ensure the continued achievement of C max /MIC targets. Figure 2 represents a proposed dosing algorithm to maximize the probability of achieving the target C max /MIC of 10 in patients with pneumonia caused by gram-negative organisms. This C max /MIC target was chosen to achieve the maximum probability of response, considering the MIC 90 s of our institution's gram-negative organisms and the upper limit of aminoglycoside dose tolerability. However, other C max /MIC targets may be more appropriate. The probability of temperature and leukocyte count resolution by day 7 of therapy has been calculated for the following C max /MIC ratios: 4, 65%; 5, 71%; 6, 76%; 7, 81%; 8, 84%; 9, 88%; and 10, 90% (7). For example, in our patient population, more resistant organisms with aminoglycoside MICs of 2 and 4 g/ml would require median loading doses of 10.6 (8.6 to 13.4) and 21.3 (17.2 to 26.9) mg/kg, respectively, to achieve the C max /MIC target of 10. As the safety of these doses has not been established, targeting a C max /MIC of 5 in this situation may be a more reasonable approach, even though this C max /MIC does not give a Ն90% probability of a temperature or leukocyte response. In addition, the combination of aminoglycosides with an additive or synergistic time-dependent killing agent may be essential. As each institution has different patient population profiles and different bacterial organism sensitivities, early pharmacokinetic optimization is important.
Achieving a postdistributional aminoglycoside C max /MIC of 10 may decrease the time to therapeutic response in our patient population (7) . Using an MIC 90 of 1 g/ml, with an aminoglycoside volume of distribution of 20.2 (16.3 to 27.8) liters (0.32 [0.27 to 0.38] liter/kg) and a moderate degree of renal impairment, administering an aminoglycoside loading dose of 7 mg/kg with IPM with the first dose will rapidly achieve this goal. As all patients in this analysis had their aminoglycoside dosing intervals adjusted to achieve a C min of 0.5 g/ml (65% were dosed every 8 to 18 h), these data should not be extrapolated to empirical single-daily-dose regimens. The aggressive C max /MIC target of 10 may not be practical for all institutions, as aminoglycoside doses for organisms for which the MIC 90 s are greater than 1 g/ml may be beyond a clinician's acceptable range. However, these data stress the need for rapid pharmacokinetic optimization of individual aminoglycoside dosing.
By reducing the time to therapeutic response, overall courses of aminoglycoside therapy may be shorter; with a potential reduction in the incidence of nephrotoxicity. Furthermore, to reduce the risk of aminoglycoside toxicity, a reduction in dose (and thus overall exposure) can be achieved by utilizing the aminoglycoside with the lowest MIC for the isolated bacterium. Our institution's microbiology data for 1996 illustrate the importance of rapid organism identification and accurate MIC data to optimize aminoglycoside regimens. This analysis has demonstrated that two commonly used methods for determining the dosages of aminoglycosides (clinician determined and traditional C max targets) fall short of achieving optimal pharmacodynamic targets.
As this is a retrospective analysis, it will be necessary to conduct a prospective clinical trial to determine if an aggressive aminoglycoside regimen with subsequent adjustment based on an organism-specific MIC to achieve a C max /MIC of 10 and a C min of Ͻ2 g/ml in patients with pneumonia caused by gram-negative organisms can reduce the time to therapeutic response and potentially reduce the length of stay in the hospital without increasing toxicity.
